

# Debbie S Gipson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9323503/publications.pdf>

Version: 2024-02-01

153  
papers

7,838  
citations

57758

44  
h-index

56724

83  
g-index

154  
all docs

154  
docs citations

154  
times ranked

8039  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Child and caregiver perspectives on access to psychosocial and educational support in pediatric chronic kidney disease: a focus group study. <i>Pediatric Nephrology</i> , 2023, 38, 249-260.  | 1.7 | 2         |
| 2  | Patient and caregiver perspectives on blood pressure in children with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1330-1339.  | 0.7 | 2         |
| 3  | Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2022, 79, 570-581. | 1.9 | 15        |
| 4  | Determinants of medication adherence in childhood nephrotic syndrome and associations of adherence with clinical outcomes. <i>Pediatric Nephrology</i> , 2022, 37, 1585-1595.  | 1.7 | 1         |
| 5  | Perspectives of Clinicians on Shared Decision Making in Pediatric CKD: A Qualitative Study. <i>American Journal of Kidney Diseases</i> , 2022, 80, 241-250.  | 1.9 | 3         |
| 6  | Unsupervised machine learning for identifying important visual features through bag-of-words using histopathology data from chronic kidney disease. <i>Scientific Reports</i> , 2022, 12, 4832.  | 3.3 | 14        |
| 7  | Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1193-1207.              | 6.1 | 33        |
| 8  | Gluten-Free Diet in Childhood Difficult-to-Treat Nephrotic Syndrome: A Pilot Feasibility Study. <i>Glomerular Diseases</i> , 2022, 2, 176-183.   | 1.0 | 2         |
| 9  | Adult survivors of idiopathic childhood onset nephrotic syndrome. <i>Pediatric Nephrology</i> , 2021, 36, 1731-1737.   | 1.7 | 16        |
| 10 | Tryptophan levels associate with incident cardiovascular disease in chronic kidney disease. CKJ: <i>Clinical Kidney Journal</i> , 2021, 14, 1097-1105.   | 2.9 | 19        |
| 11 | Innovating and invigorating the clinical trial infrastructure for glomerular diseases. <i>Kidney International</i> , 2021, 99, 519-523.  | 5.2 | 4         |
| 12 | A pediatric gateway initiative for glomerular disease: introducing PIONEER. <i>Kidney International</i> , 2021, 99, 515-518.   | 5.2 | 4         |
| 13 | Inpatient Pediatric CKD Health Care Utilization and Mortality in the United States. <i>American Journal of Kidney Diseases</i> , 2021, 77, 500-508.  | 1.9 | 9         |
| 14 | Health-related quality of life in children with chronic kidney disease is affected by the number of medications. <i>Pediatric Nephrology</i> , 2021, 36, 1307-1310.  | 1.7 | 4         |
| 15 | Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis. <i>American Journal of Kidney Diseases</i> , 2021, 77, 216-225.   | 1.9 | 23        |
| 16 | Kidney Injury Molecule-1 and Periostin Urinary Excretion and Tissue Expression Levels and Association with Glomerular Disease Outcomes. <i>Complex Psychiatry</i> , 2021, 1, 45-59.  | 0.9 | 4         |
| 17 | APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. <i>Pediatric Nephrology</i> , 2021, 36, 2747-2757.   | 1.7 | 3         |
| 18 | FC 023SAFETY OF BARDOXOLONE METHYL IN PEDIATRIC PATIENTS WITH ALPORT SYNDROME IN CARDINAL PHASE 3 TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .  | 0.7 | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Improving data quality in observational research studies: Report of the Cure Glomerulonephropathy (CureGN) network. Contemporary Clinical Trials Communications, 2021, 22, 100749.  | 1.1 | 7         |
| 20 | Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. Kidney International Reports, 2021, 6, 2575-2584. | 0.8 | 15        |
| 21 | Health-Related Quality of Life in Focal Segmental Glomerular Sclerosis and Minimal Change Disease: A Qualitative Study of Children and Adults to Inform Patient-Reported Outcomes. Kidney Medicine, 2021, 3, 484-497.e1.  | 2.0 | 5         |
| 22 | The Development and Use of an EHR-Linked Database for Glomerular Disease Research and Quality Initiatives. Glomerular Diseases, 2021, 1, 173-179.   | 1.0 | 3         |
| 23 | Validating a Computable Phenotype for Nephrotic Syndrome in Children and Adults Using PCORnet Data. Kidney360, 2021, 2, 1979-1986.  | 2.1 | 6         |
| 24 | Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.   | 5.2 | 7         |
| 25 | Functional Magnetic Resonance Imaging Findings in Children and Adolescents With Chronic Kidney Disease: Preliminary Findings. Seminars in Nephrology, 2021, 41, 462-475.  | 1.6 | 7         |
| 26 | Urinary Epidermal Growth Factor as a Marker of Disease Progression in Children With Nephrotic Syndrome. Kidney International Reports, 2020, 5, 414-425.   | 0.8 | 10        |
| 27 | Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. Kidney International Reports, 2020, 5, 1679-1689.  | 0.8 | 17        |
| 28 | The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.                   | 2.9 | 14        |
| 29 | IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatric Nephrology, 2020, 35, 1529-1561.   | 1.7 | 179       |
| 30 | A longitudinal examination of parent-reported emotional-behavioral functioning of children with mild to moderate chronic kidney disease. Pediatric Nephrology, 2020, 35, 1287-1295.   | 1.7 | 19        |
| 31 | Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis. Kidney International Reports, 2020, 5, 1228-1239.   | 0.8 | 5         |
| 32 | Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrologyâ€™Children and Adolescents (SONG-KIDS) consensus workshops. Kidney International, 2020, 98, 553-565.   | 5.2 | 58        |
| 33 | Time to Initiation of Antihypertensive Therapy After Onset of Elevated Blood Pressure in Patients With Primary Proteinuric Kidney Disease. Kidney Medicine, 2020, 2, 131-138.   | 2.0 | 2         |
| 34 | Dynamic treatment regimens in small n, sequential, multiple assignment, randomized trials: An application in focal segmental glomerulosclerosis. Contemporary Clinical Trials, 2020, 92, 105989.  | 1.8 | 7         |
| 35 | Toward Patient-Centered Innovation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1522-1530.   | 4.5 | 8         |
| 36 | Pediatric Immunization Practices in Nephrotic Syndrome: An Assessment of Provider and Parental Knowledge. Frontiers in Pediatrics, 2020, 8, 619548.   | 1.9 | 5         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN). <i>Kidney International Reports</i> , 2019, 4, 1725-1734.                  | 0.8 | 13        |
| 38 | Text Messaging for Disease Monitoring in Childhood Nephrotic Syndrome. <i>Kidney International Reports</i> , 2019, 4, 1066-1074.   | 0.8 | 9         |
| 39 | Creation of a Multicenter Pediatric Inpatient Data Repository Derived from Electronic Health Records. <i>Applied Clinical Informatics</i> , 2019, 10, 307-315.   | 1.7 | 11        |
| 40 | Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease. <i>Kidney International Reports</i> , 2019, 4, 1608-1616.   | 0.8 | 20        |
| 41 | Soluble ST2 and Galectin-3 and Progression of CKD. <i>Kidney International Reports</i> , 2019, 4, 103-111.   | 0.8 | 41        |
| 42 | Using PROMIS® to create clinically meaningful profiles of nephrotic syndrome patients.. <i>Health Psychology</i> , 2019, 38, 410-421.  | 1.6 | 16        |
| 43 | Plasma Zonulin Levels in Childhood Nephrotic Syndrome. <i>Frontiers in Pediatrics</i> , 2019, 7, 197.  | 1.9 | 12        |
| 44 | Identifying Important Outcomes for Young People With CKD and Their Caregivers: A Nominal Group Technique Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 82-94.                          | 1.9 | 42        |
| 45 | Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease. <i>JAMA Cardiology</i> , 2019, 4, 353.  | 6.1 | 77        |
| 46 | Health-related quality of life in glomerular disease. <i>Kidney International</i> , 2019, 95, 1209-1224.   | 5.2 | 38        |
| 47 | US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. <i>American Journal of Kidney Diseases</i> , 2019, 73, A7-A8.                                       | 1.9 | 680       |
| 48 | Differential network enrichment analysis reveals novel lipid pathways in chronic kidney disease. <i>Bioinformatics</i> , 2019, 35, 3441-3452.  | 4.1 | 26        |
| 49 | CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. <i>American Journal of Kidney Diseases</i> , 2019, 73, 218-229.               | 1.9 | 68        |
| 50 | An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 414-421.                 | 4.5 | 57        |
| 51 | Assessing responsiveness over time of the PROMIS® pediatric symptom and function measures in cancer, nephrotic syndrome, and sickle cell disease. <i>Quality of Life Research</i> , 2018, 27, 249-257. | 3.1 | 45        |
| 52 | Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome. <i>Kidney International Reports</i> , 2018, 3, 115-121.  | 0.8 | 21        |
| 53 | DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2745-2754.                        | 6.1 | 128       |
| 54 | Gut Microbial Product Predicts Cardiovascular Risk in Chronic Kidney Disease Patients. <i>American Journal of Nephrology</i> , 2018, 48, 269-277.  | 3.1 | 32        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. <i>Kidney International Reports</i> , 2018, 3, 1373-1384.                      | 0.8 | 39        |
| 56 | Brain abnormalities in children and adolescents with chronic kidney disease. <i>Pediatric Research</i> , 2018, 84, 387-392.   | 2.3 | 30        |
| 57 | Child and Parental Perspectives on Communication and Decision Making in Pediatric CKD: A Focus Group Study. <i>American Journal of Kidney Diseases</i> , 2018, 72, 547-559.   | 1.9 | 46        |
| 58 | NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome. <i>Kidney International Reports</i> , 2018, 3, 439-446.   | 0.8 | 10        |
| 59 | GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. <i>American Journal of Kidney Diseases</i> , 2018, 72, 519-528.  | 1.9 | 82        |
| 60 | Consent for Genetic Biobanking in a Diverse Multisite CKD Cohort. <i>Kidney International Reports</i> , 2018, 3, 1267-1275.   | 0.8 | 9         |
| 61 | Provider perspectives on treatment decision-making in nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i106-i114.   | 0.7 | 2         |
| 62 | Range and Heterogeneity of Outcomes in Randomized Trials of Pediatric Chronic Kidney Disease. <i>Journal of Pediatrics</i> , 2017, 186, 110-117.e11.  | 1.8 | 35        |
| 63 | Improving the evidence for the management of childhood nephrotic syndrome. <i>Kidney International</i> , 2017, 92, 21-23.   | 5.2 | 12        |
| 64 | Learning to live with nephrotic syndrome: experiences of adult patients and parents of children with nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i98-i105.                                     | 0.7 | 14        |
| 65 | Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET). <i>Kidney International Reports</i> , 2017, 2, 654-664.   | 0.8 | 36        |
| 66 | Development of a Pediatric Adverse Events Terminology. <i>Pediatrics</i> , 2017, 139, .   | 2.1 | 20        |
| 67 | Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire. <i>American Journal of Kidney Diseases</i> , 2017, 70, 532-540.                          | 1.9 | 12        |
| 68 | Patient-Reported Outcomes in Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 140-148.  | 4.5 | 24        |
| 69 | Responsiveness of the PROMIS® measures to changes in disease status among pediatric nephrotic syndrome patients: a Midwest pediatric nephrology consortium study. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 166. | 2.4 | 19        |
| 70 | Changing the Paradigm for the Treatment and Development of New Therapies for FSGS. <i>Frontiers in Pediatrics</i> , 2016, 4, 25.  | 1.9 | 8         |
| 71 | Neurocognitive, Social-Behavioral, and Adaptive Functioning in Preschool Children with Mild to Moderate Kidney Disease. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2016, 37, 231-238.                        | 1.1 | 34        |
| 72 | Fibroblast growth factor-23 and chronic allograft injury in pediatric renal transplant recipients: a Midwest Pediatric Nephrology Consortium study. <i>Pediatric Transplantation</i> , 2016, 20, 378-387.                     | 1.0 | 3         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | A unified framework for evaluating the risk of re-identification of text de-identification tools. <i>Journal of Biomedical Informatics</i> , 2016, 63, 174-183.                                   | 4.3 | 14        |
| 74 | The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases. <i>Kidney International</i> , 2016, 90, 1080-1089.         | 5.2 | 51        |
| 75 | Standardised Outcomes in Nephrology Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. <i>Trials</i> , 2016, 17, 401. | 1.6 | 41        |
| 76 | The Effect of a Gluten-Free Diet in Children With Difficult-to-Manage Nephrotic Syndrome. <i>Pediatrics</i> , 2016, 138, .  | 2.1 | 17        |
| 77 | A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 253-255.       | 1.9 | 11        |
| 78 | Complete Remission in the Nephrotic Syndrome Study Network. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 81-89.   | 4.5 | 53        |
| 79 | Optimizing Enrollment of Patients into Nephrology Research Studies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 512-517.                                     | 4.5 | 10        |
| 80 | Vitamin D in incident nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. <i>Pediatric Nephrology</i> , 2016, 31, 465-472.   | 1.7 | 23        |
| 81 | Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method. <i>Quality of Life Research</i> , 2016, 25, 13-23.                                  | 3.1 | 148       |
| 82 | Patient Engagement in Neurological Clinical Trials Design: A Conference Summary. <i>Clinical and Translational Science</i> , 2015, 8, 776-778.  | 3.1 | 12        |
| 83 | Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1443-1448.         | 6.1 | 104       |
| 84 | Novel Therapies for FSGS: Preclinical and Clinical Studies. <i>Advances in Chronic Kidney Disease</i> , 2015, 22, e1-e6.  | 1.4 | 31        |
| 85 | US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. <i>American Journal of Kidney Diseases</i> , 2015, 66, A7.                                     | 1.9 | 484       |
| 86 | Matching the Genotype in Resolution: Innovative Ways of Phenotype Capture. <i>Seminars in Nephrology</i> , 2015, 35, 279-290.   | 1.6 | 2         |
| 87 | The impact of disease duration on quality of life in children with nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. <i>Pediatric Nephrology</i> , 2015, 30, 1467-1476.        | 1.7 | 49        |
| 88 | Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. <i>BMC Nephrology</i> , 2015, 16, 111.               | 1.8 | 63        |
| 89 | A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. <i>Kidney International</i> , 2015, 87, 564-574.   | 5.2 | 111       |
| 90 | HLA-DQA1 and PLCG2 Are Candidate Risk Loci for Childhood-Onset Steroid-Sensitive Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1701-1710.            | 6.1 | 118       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS ONE, 2015, 10, e0136558.   | 2.5 | 54        |
| 92  | Hypertension and Health Outcomes in the PICU. Pediatric Critical Care Medicine, 2014, 15, 417-427.   | 0.5 | 18        |
| 93  | Childhood Onset Nephrotic Syndrome. , 2014, , 23-31.   |     | 3         |
| 94  | Focal Segmental Glomerulosclerosis. , 2014, , 170-175.   |     | 1         |
| 95  | Validation of the KDIGO acute kidney injury criteria in a pediatric critical care population. Intensive Care Medicine, 2014, 40, 1481-1488.  | 8.2 | 188       |
| 96  | Gaining the Patient Reported Outcomes Measurement Information System (PROMIS) perspective in chronic kidney disease: a Midwest Pediatric Nephrology Consortium study. Pediatric Nephrology, 2014, 29, 2347-2356. | 1.7 | 47        |
| 97  | Treatment of FSGS in Children. Advances in Chronic Kidney Disease, 2014, 21, 194-199.  | 1.4 | 26        |
| 98  | The authors reply. Pediatric Critical Care Medicine, 2014, 15, 918-919.  | 0.5 | 0         |
| 99  | Gaining the PROMIS perspective from children with nephrotic syndrome: a Midwest pediatric nephrology consortium study. Health and Quality of Life Outcomes, 2013, 11, 30.  | 2.4 | 51        |
| 100 | Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium. Pediatric Nephrology, 2013, 28, 1235-1241.   | 1.7 | 22        |
| 101 | Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatric Nephrology, 2013, 28, 409-414.   | 1.7 | 91        |
| 102 | Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatric Nephrology, 2013, 28, 415-426.   | 1.7 | 218       |
| 103 | Inpatient Health Care Utilization in the United States Among Children, Adolescents, and Young Adults With Nephrotic Syndrome. American Journal of Kidney Diseases, 2013, 61, 910-917.                            | 1.9 | 36        |
| 104 | The Impact of Short Stature on Health-Related Quality of Life in Children with Chronic Kidney Disease. Journal of Pediatrics, 2013, 163, 736-741.e1.   | 1.8 | 109       |
| 105 | Association of Histologic Variants in FSGS Clinical Trial with Presenting Features and Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 399-406.                                | 4.5 | 125       |
| 106 | Renal Function and Proteinuria after Successful Immunosuppressive Therapies in Patients with FSGS. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 211-218.                              | 4.5 | 19        |
| 107 | Inpatient health care utilization by children and adolescents with systemic lupus erythematosus and kidney involvement. Arthritis Care and Research, 2013, 65, 382-390.  | 3.4 | 11        |
| 108 | Contribution of Renal and Non-Renal Clearance on Increased Total Clearance of Adalimumab in Glomerular Disease. Journal of Clinical Pharmacology, 2013, 53, 919-924.   | 2.0 | 20        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Patient Recruitment into a Multicenter Randomized Clinical Trial for Kidney Disease: Report of the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS CT). <i>Clinical and Translational Science</i> , 2013, 6, 13-20. | 3.1 | 16        |
| 110 | Public Participation in, and Awareness about, Medical Research Opportunities in the Era of Clinical and Translational Research. <i>Clinical and Translational Science</i> , 2013, 6, 88-93.                                 | 3.1 | 25        |
| 111 | Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. <i>Kidney International</i> , 2013, 83, 749-756.                                       | 5.2 | 268       |
| 112 | Recent Trends in Healthcare Utilization Among Children and Adolescents With Hypertension in the United States. <i>Hypertension</i> , 2012, 60, 296-302.   | 2.7 | 42        |
| 113 | Regarding Maas's editorial letter on serum suPAR levels. <i>Kidney International</i> , 2012, 82, 492.   | 5.2 | 6         |
| 114 | Focal segmental glomerulosclerosis. , 2012, , 212-216.  |     | 1         |
| 115 | Circulating suPAR in Two Cohorts of Primary FSGS. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 2051-2059.   | 6.1 | 202       |
| 116 | A Clinical Tool to Measure the Components of Health-Care Transition from Pediatric Care to Adult Care: The UNC TRANSITION Scale. <i>Renal Failure</i> , 2012, 34, 744-753.  | 2.1 | 146       |
| 117 | Implications of different fluid overload definitions in pediatric stem cell transplant patients requiring continuous renal replacement therapy. <i>Intensive Care Medicine</i> , 2012, 38, 663-669.                         | 8.2 | 33        |
| 118 | Prevalence of sleep disturbances in children and adolescents with chronic kidney disease. <i>Pediatric Nephrology</i> , 2012, 27, 451-459.  | 1.7 | 48        |
| 119 | Neurological Effects and Cognitive Development. , 2012, , 581-592.  |     | 0         |
| 120 | Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. <i>BMC Nephrology</i> , 2011, 12, 8.   | 1.8 | 34        |
| 121 | Neurocognitive Functioning of Children and Adolescents with Mild-to-Moderate Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1824-1830.                             | 4.5 | 150       |
| 122 | A phase 1, single-dose study of fresolimumab, an anti-TGF- $\beta$ 2 antibody, in treatment-resistant primary focal segmental glomerulosclerosis. <i>Kidney International</i> , 2011, 79, 1236-1243.                        | 5.2 | 222       |
| 123 | Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. <i>Kidney International</i> , 2011, 79, 678-685.  | 5.2 | 52        |
| 124 | Clinical trial of focal segmental glomerulosclerosis in children and young adults. <i>Kidney International</i> , 2011, 80, 868-878.   | 5.2 | 208       |
| 125 | Casual Blood Pressure and Neurocognitive Function in Children with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1831-1837.                                       | 4.5 | 74        |
| 126 | Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group. <i>American Journal of Kidney Diseases</i> , 2010, 55, 50-60.            | 1.9 | 73        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrology, 2010, 11, 2.                                   | 1.8 | 32        |
| 128 | Cognitive improvement in children with CKD after transplant. Pediatric Transplantation, 2010, 14, 887-890.  | 1.0 | 61        |
| 129 | Health-Related Quality of Life of Children With Mild to Moderate Chronic Kidney Disease. Pediatrics, 2010, 125, e349-e357.  | 2.1 | 182       |
| 130 | Neurodevelopmental Status and Adaptive Behaviors in Preschool Children with Chronic Kidney Disease. Journal of Special Education, 2009, 43, 45-51.                      | 1.7 | 10        |
| 131 | Predictors of Relapse and End Stage Kidney Disease in Proliferative Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1962-1967. | 4.5 | 69        |
| 132 | Phase I Trial of Rosiglitazone in FSGS. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 39-47.  | 4.5 | 34        |
| 133 | Management patterns of childhood-onset nephrotic syndrome. Pediatric Nephrology, 2009, 24, 2193-2201.   | 1.7 | 46        |
| 134 | Social and behavioural functioning in paediatric chronic kidney disease. Child: Care, Health and Development, 2009, 35, 832-840.  | 1.7 | 19        |
| 135 | Management of Childhood Onset Nephrotic Syndrome. Pediatrics, 2009, 124, 747-757.   | 2.1 | 247       |
| 136 | Renal Manifestations of Systemic Illness in Children. Seminars in Nephrology, 2009, 29, 360-369.  | 1.6 | 2         |
| 137 | Neurodevelopmental Issues in Chronic Renal Disease. , 2008, , 733-741.  |     | 2         |
| 138 | Pediatric chronic kidney disease in North Carolina. North Carolina Medical Journal, 2008, 69, 208-14.   | 0.2 | 5         |
| 139 | Brief Report: Intellectual and Academic Functioning in Pediatric Chronic Kidney Disease. Journal of Pediatric Psychology, 2007, 32, 1011-1017.                          | 2.1 | 72        |
| 140 | The central nervous system in childhood chronic kidney disease. Pediatric Nephrology, 2007, 22, 1703-1710.  | 1.7 | 47        |
| 141 | Therapeutic approach to FSGS in children. Pediatric Nephrology, 2007, 22, 28-36.  | 1.7 | 26        |
| 142 | Clinical predictors of neurocognitive deficits in children with chronic kidney disease. Pediatric Nephrology, 2007, 22, 565-572.  | 1.7 | 78        |
| 143 | Memory and Executive Functions in Pediatric Chronic Kidney Disease. Child Neuropsychology, 2006, 12, 391-405.   | 1.3 | 92        |
| 144 | Differential risk of remission and ESRD in childhood FSGS. Pediatric Nephrology, 2006, 21, 344-349.   | 1.7 | 128       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Trends in treatment and outcomes of survival of adolescents initiating end-stage renal disease care in the United States of America. <i>Pediatric Nephrology</i> , 2006, 21, 1020-1026. | 1.7 | 115       |
| 146 | Kidney in systemic lupus erythematosus and vasculitis. , 2006, , 245-260.   |     | 0         |
| 147 | The clinical trial imperative. <i>Pediatric Nephrology</i> , 2005, 20, 5-9.   | 1.7 | 1         |
| 148 | The differential effect of race among pediatric kidney transplant recipients with focal segmental glomerulosclerosis. <i>American Journal of Kidney Diseases</i> , 2004, 43, 1082-1090. | 1.9 | 30        |
| 149 | The nervous system and chronic kidney disease in children. <i>Pediatric Nephrology</i> , 2004, 19, 832-9.   | 1.7 | 36        |
| 150 | A measure of success in kidney transplantations. <i>Pediatric Transplantation</i> , 2004, 8, 104-105.   | 1.0 | 7         |
| 151 | Intraperitoneal administration of recombinant human growth hormone in children with end-stage renal disease. <i>Pediatric Nephrology</i> , 2001, 16, 29-34.                             | 1.7 | 5         |
| 152 | Anthropometric measures and risk of death in children with end-stage renal disease. <i>American Journal of Kidney Diseases</i> , 2000, 36, 811-819.                                     | 1.9 | 204       |
| 153 | The Health Economic Impact of Nephrotic Syndrome in the United States. <i>Kidney360</i> , 0, , 10.34067/KID.0005072021.   | 2.1 | 3         |